CJC-1295 vs Liraglutide

CJC-1295 binds to and activates pituitary GHRH receptors, stimulating pulsatile GH secretion. The DAC modification enables covalent binding to albumin, dramatically extending the active peptide half-life. This sustained GH pulse pattern is intended to mimic physiological GH release more closely than shorter-acting GHRH analogues.

CJC-1295 (DAC-GRF) is a synthetic 30-amino-acid GHRH analog incorporating a Drug Affinity Complex (DAC) modification — trans-4-aminomethylcyclohexane carboxylic acid — that enables covalent binding to circulating albumin, dramatically extending the plasma half-life from minutes (as with native GHRH) to approximately 6–8 days and enabling once or twice-weekly dosing for sustained GH and IGF-1 elevation. The extended half-life allows CJC-1295 to act as a continuous GHRH-receptor agonist at pituitary somatotrophs rather than producing pulsatile stimulation, stimulating cumulative GH secretion and downstream IGF-1 production; this pharmacokinetic profile distinguishes it from short-acting GHRH analogs such as sermorelin and positions it for research in GH axis restoration. A Phase 1 dose-escalation RCT in healthy adults published in the Journal of Clinical Endocrinology and Metabolism (2006) demonstrated dose-dependent and sustained increases in mean GH and IGF-1 concentrations following single-dose administration, establishing the only indexed human pharmacokinetic and pharmacodynamic data for this compound; all other indexed literature consists of anti-doping detection methods. CJC-1295 has no FDA approval and no approved therapeutic indication in any jurisdiction; it is available only as a research compound and the clinical evidence base is limited to a single Phase 1 safety and PK study in healthy subjects, with no Phase 2 or Phase 3 data addressing efficacy for any specific indication. CJC-1295 and ipamorelin combination: CJC-1295 is most commonly studied in combination with ipamorelin, a selective GHRP (growth hormone-releasing peptide), because the two compounds act on complementary pathways to stimulate GH release. CJC-1295 activates the GHRH receptor at pituitary somatotrophs, providing a sustained permissive signal for GH secretion; ipamorelin activates the ghrelin receptor (GHS-R1a), producing a discrete GH pulse with high selectivity and without meaningfully elevating cortisol or prolactin. Research and clinical interest in the combination centers on the synergistic GH pulse amplitude achieved when both pathways are stimulated together — greater than either compound alone. The pharmacokinetic profiles are complementary: CJC-1295's extended half-life (6–8 days) provides a stable GHRH background, while ipamorelin's short half-life (approximately 2 hours) allows timed pulsatile stimulation. In clinical research contexts, CJC-1295 is typically administered subcutaneously one to two times weekly to maintain a sustained GH baseline, while ipamorelin is dosed more frequently — daily or multiple times per day — to generate GH pulses aligned with sleep or exercise. A triple-stack combining CJC-1295, ipamorelin, and sermorelin is referenced in some clinical contexts for additive GH axis stimulation, though evidence supporting the triple combination beyond individual compound data is limited. All dosing references are for research contexts only; no approved clinical protocols exist for any of these combinations. Subcutaneous vs intramuscular injection for CJC-1295: CJC-1295 is administered exclusively via subcutaneous injection in all published research — intramuscular injection is not used for this compound. Subcutaneous injection into abdominal fat or thigh tissue results in slower, more consistent absorption suitable for the depot-like pharmacokinetic profile that CJC-1295's DAC modification already provides. Rotation of injection sites is recommended to avoid lipohypertrophy at repeated injection locations. Injection technique, site preparation with an alcohol swab, and proper needle gauge selection (typically 27–31G for subcutaneous peptide injection) are standard considerations across all subcutaneous peptide administration contexts.

GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management and type 2 diabetes, formulated as a daily subcutaneous injection that reduces appetite by activating GLP-1 receptors in the hypothalamus and brainstem. It mimics endogenous incretin hormone action — slowing gastric emptying, increasing satiety signaling, and reducing caloric intake through central and peripheral GLP-1 receptor pathways. The landmark SCALE Obesity trial, a large multicenter randomized controlled trial published in the New England Journal of Medicine, demonstrated significant weight loss of approximately 8% at 56 weeks with 3.0 mg liraglutide (Saxenda) compared to placebo. Liraglutide is an FDA-approved prescription medication available as Victoza (type 2 diabetes, 1.8 mg) and Saxenda (chronic weight management, 3.0 mg); it requires physician supervision and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma. Liraglutide vs semaglutide: key distinctions Liraglutide is a daily subcutaneous injection; semaglutide is weekly. The dosing frequency difference reflects half-life: liraglutide's plasma half-life is approximately 13 hours, requiring daily administration to maintain therapeutic levels; semaglutide's albumin-binding modification extends its half-life to approximately 7 days. For weight management outcomes, semaglutide significantly outperforms liraglutide: STEP 1 reported ~15% mean weight reduction vs ~8% with liraglutide in SCALE. The practical implication is that liraglutide is generally appropriate for patients who have contraindications to once-weekly GLP-1 therapy, who are already established on liraglutide for T2D (Victoza), or who are in a jurisdiction where semaglutide is less accessible. Liraglutide has a longer post-approval safety record — it was approved in 2010 for T2D and 2014 for obesity management — while semaglutide's obesity indication was approved in 2021. The LEADER trial established cardiovascular risk reduction for liraglutide in T2D patients, adding an outcomes benefit beyond glucose control. Liraglutide cost and access: As a branded pharmaceutical (Victoza, Saxenda), liraglutide requires a prescription from a licensed provider. Saxenda (3.0mg/day for obesity) has an approximate monthly list price of $1,300–$1,500 USD; actual cost varies by insurance coverage and assistance programs. Generic or biosimilar liraglutide is not yet widely available in the US market. Compounding pharmacies do not commonly produce liraglutide formulations given the availability of approved branded products. Providers offering GLP-1 agonist programs that include liraglutide are searchable in the PeptideBase provider directory.